Increasing HDL Cholesterol Levels
- 8 April 2004
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (15) , 1491-1494
- https://doi.org/10.1056/nejmp048023
Abstract
In the past decade, high-density lipoproteins (HDL) have emerged as a new potential therapeutic target for the treatment of cardiovascular disease. The key role of HDL as a carrier of excess cellular cholesterol in the reverse cholesterol transport pathway is believed to provide protection against atherosclerosis. In reverse cholesterol transport, peripheral tissues (e.g., vessel-wall macrophages) remove their excess cholesterol through the ATP-binding cassette transporter 1 (ABCA1) to poorly lipidated apolipoprotein A-I, forming pre-β-HDL. Lecithin–cholesterol acyltransferase then esterifies free cholesterol to cholesteryl esters, converting pre-β-HDL to mature spherical α-HDL (see Figure).HDL cholesterol is transported to the liver by two pathways: . . .Keywords
This publication has 6 references indexed in Scilit:
- Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL CholesterolNew England Journal of Medicine, 2004
- High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary SyndromesJAMA, 2003
- Cholesteryl Ester Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cellsCurrent Opinion in Lipidology, 2002
- Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma CholesterolCirculation, 2002